Glycotest

Glycotest Inc. was founded with the mission to revolutionize the early detection and treatment of liver diseases through non-invasive blood testing technology. The company's vision is to provide accessible and accurate diagnostics for liver cancers, particularly hepatocellular carcinoma (HCC), and fibrosis-cirrhosis. Glycotest's innovative blood tests aim to detect these conditions at an early stage, thereby improving patient outcomes and reducing the global burden of liver disease. Their market focus includes individuals at risk due to chronic liver conditions such as viral hepatitis B and C.

Notable figures associated with Glycotest include key investors and advisors from the biotechnology and healthcare sectors, though specific names are not provided. The company has achieved significant milestones in developing its proprietary diagnostic technology, which has the potential to transform liver disease management. By offering a non-invasive alternative to traditional diagnostic methods, Glycotest is poised to make a substantial impact on global healthcare, particularly in improving early detection rates and patient survival for liver-related conditions.